Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant s1 antigen
- Development stage
- Unknown
- Lead developer
- Hospital do Coração São Paulo
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Recombinant S1 antigen is a protein subunit vaccine candidate developed by Hospital do Coração (HCor) in Brazil for the prevention of COVID-19. The vaccine utilizes the S1 subunit of the SARS-CoV-2 spike protein, which contains the receptor-binding domain (RBD) responsible for mediating viral entry into host cells via the ACE2 receptor. By presenting this specific protein fragment to the immune system, the vaccine aims to elicit a targeted immune response, including the production of neutralizing antibodies. It has been evaluated in Phase 1/2 clinical trials (NCT05142553) as a heterologous booster dose for individuals who have already completed a primary vaccination series with other COVID-19 vaccines, such as CoronaVac, AstraZeneca (ChAdOx1), or Janssen (Ad26.COV2.S).
- Other names
- S1-HCorS-1-HCorS 1-HCorHCor COVID-19 vaccine
02
Targets
S1 (SARS-CoV-2 spike S1 subunit)
Beyond the preview
Go deeper on recombinant s1 antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant s1 antigen.